mytomorrows - Director, Global Access

• Strategic accountabilities • Define and evolve global access and post-MA readiness strategies across the portfolio, aligned with corporate priorities, partner objectives, and regulatory constraints. • Set access prioritization and market sequencing strategy based on access feasibility, health system readiness, risk profile, and long-term sustainability. • Shape target access models by market, including expanded access-only, transitional access, and post-MA handover models, and define the strategic principles governing each. • Design the access-related capabilities, governance structures, and operating models required to prepare the organization for post-MA activities. • Establish clear decision frameworks for transitioning programs from expanded access to post-MA environments, including role boundaries, handover points, and risk ownership. • Advise the CEO on access-related risks, trade-offs, and investment priorities, informed by ongoing monitoring of global policy, reimbursement, and expanded access trends. • Together with the Pharma Partnerships team, shape the strategic access value proposition for pharma partners, positioning Global Access programs as part of a broader, compliant access and post-MA journey • Operational accountabilities • Enable and be accountable for program performance, access outcomes, and sustainability across assigned regions, in line with Global Access strategy. • Translate global access and post-MA readiness strategies into locally appropriate, compliant execution models. • Own the post-signature access enablement layer, including field infrastructure, (sub)distributor governance, and medical field capabilities. • Build, onboard, and oversee (sub)distributor networks supporting paid-for and free-of-charge EAPs, with robust governance, training, and audit-ready oversight. • Build and scale local, high-performing Medical Science Liaison teams to deliver high-quality, non-promotional medical-scientific support, ensuring clear separation from commercial and performance-driven activities. • Partner closely with EAP Operations, Legal, Compliance, and Commercial stakeholders to ensure aligned, ethical, and regulatory-compliant execution. • Engage, where appropriate and within approved governance frameworks, with governments, payors, and healthcare system stakeholders to support aligned and compliant access pathways. • Identify, assess, and mitigate execution- and transition-related risks across markets, partners, and field teams. • Post-signature delivery and post-MA readiness. • Ensure accurate forecasting, CRM tracking (HubSpot), performance monitoring, and structured reporting. • Partner with the Pharma Partnerships team during pre-signature discussions to shape realistic, compliant global access approaches, assess execution feasibility, and set clear expectations for post-signature delivery and post-MA readiness. • Support audits, inspections, and partner reviews related to access execution and readiness • What success looks like: • You have developed a clear understanding of the Global Access portfolio, regional priorities, and the regulatory boundaries governing EAPs. • A baseline execution and governance framework is in place for distributors and field teams, including training requirements, escalation pathways, and documentation standards, informed by longer-term scalability and post-MA readiness considerations. • Strategic plans including priority markets are defined across the portfolio, based on strategic access potential, feasibility, and risk profile, and due diligence has started on potential (sub)distributor partners. • You are recognized internally as a trusted, compliance-minded leader who combines strategic access thinking with strong execution discipline. • Approved global access and post-MA readiness strategies are actively guiding execution decisions, market sequencing, and resource allocation across regions. • Priority (sub)distributors are onboarded with strong governance, training, and oversight mechanisms, aligned with both immediate execution needs and longer-term scalability. • Local MSL capability is in place in priority markets, operating fully within regulatory and medical standards and supporting medical readiness for post-MA activities. • Program performance and access-related revenue outcomes are achieved without compliance findings or audit issues. • You are trusted internally and by partners as a leader who enables access responsibly, balances strategic intent with operational discipline, and protects patient and company interests. • A stable, scalable, and audit-ready global access and post-MA enablement structure is operating across multiple geographies, aligned with the organization’s long-term access and growth strategy. • Distributor and MSL models are mature, well-governed, and consistently compliant with global and local requirements, and are designed to support sustained access and transition toward post-MA activities. • Execution and access insights are systematically informing program expansions, renewals, sales positioning, and the evolution of future Global Access and post-MA strategies. • The Global Access function is viewed internally and externally as a strategic and operational benchmark for compliant access enablement. • Pharma partners demonstrate high confidence in myTomorrows’ ability to support responsible, sustainable access from early access through post-MA transition. • Trusted, compliant engagement models with governments, payors, and healthcare system stakeholders are established and embedded, supporting sustainable access pathways over time. • Equal opportunities